Log in to save to my catalogue

Hepatocyte-specific CCAAT/enhancer binding protein [alpha] restricts liver fibrosis progression

Hepatocyte-specific CCAAT/enhancer binding protein [alpha] restricts liver fibrosis progression

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3037083193

Hepatocyte-specific CCAAT/enhancer binding protein [alpha] restricts liver fibrosis progression

About this item

Full title

Hepatocyte-specific CCAAT/enhancer binding protein [alpha] restricts liver fibrosis progression

Publisher

Ann Arbor: American Society for Clinical Investigation

Journal title

The Journal of clinical investigation, 2024-04, Vol.134 (7), p.1-15

Language

English

Formats

Publication information

Publisher

Ann Arbor: American Society for Clinical Investigation

More information

Scope and Contents

Contents

Metabolic dysfunction-associated steatohepatitis (MASH)--previously described as nonalcoholic steatohepatitis (NASH)--is a major driver of liver fibrosis in humans, while liver fibrosis is a key determinant of all-cause mortality in liver disease independent of MASH occurrence. CCAAT/enhancer binding protein [alpha] (CEBPA), as a versatile ligandin...

Alternative Titles

Full title

Hepatocyte-specific CCAAT/enhancer binding protein [alpha] restricts liver fibrosis progression

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_3037083193

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3037083193

Other Identifiers

ISSN

0021-9738

E-ISSN

1558-8238

DOI

10.1172/JCI166731

How to access this item